Dianthus Therapeutics (NASDAQ:DNTH) Shares Gap Up on Analyst Upgrade

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) gapped up before the market opened on Thursday after Raymond James raised their price target on the stock from $34.00 to $51.00. The stock had previously closed at $23.34, but opened at $24.36. Raymond James currently has an outperform rating on the stock. Dianthus Therapeutics shares last traded at $23.94, with a volume of 9,679 shares traded.

DNTH has been the subject of a number of other research reports. Stifel Nicolaus began coverage on shares of Dianthus Therapeutics in a research note on Thursday, February 15th. They issued a “buy” rating and a $44.00 price target for the company. Wedbush lifted their price target on shares of Dianthus Therapeutics from $24.00 to $33.00 and gave the stock an “outperform” rating in a research note on Friday, March 22nd. Finally, Jefferies Financial Group lifted their price target on shares of Dianthus Therapeutics from $22.00 to $39.00 and gave the stock a “buy” rating in a research note on Friday, March 22nd. Five analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $42.40.

Institutional Trading of Dianthus Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Tower Research Capital LLC TRC acquired a new stake in Dianthus Therapeutics during the fourth quarter worth approximately $25,000. Citigroup Inc. acquired a new stake in Dianthus Therapeutics during the third quarter worth approximately $53,000. Dimensional Fund Advisors LP acquired a new stake in Dianthus Therapeutics during the fourth quarter worth approximately $153,000. Northern Trust Corp acquired a new position in shares of Dianthus Therapeutics in the 4th quarter valued at $159,000. Finally, Acadian Asset Management LLC acquired a new position in shares of Dianthus Therapeutics in the 3rd quarter valued at $303,000. Institutional investors and hedge funds own 47.53% of the company’s stock.

Dianthus Therapeutics Price Performance

The business’s fifty day moving average price is $25.81 and its 200 day moving average price is $17.23.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its earnings results on Thursday, March 21st. The company reported ($0.71) EPS for the quarter, beating analysts’ consensus estimates of ($1.11) by $0.40. The business had revenue of $0.46 million during the quarter, compared to analyst estimates of $0.73 million. Analysts predict that Dianthus Therapeutics, Inc. will post -1.92 earnings per share for the current fiscal year.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.